Related Experiment Video
Updated: Mar 22, 2026
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
SENOPAUSE: Evaluation of an ASCO-Derived Clinical Proxy for Axillary Risk Stratification in a Retrospective Cohort
Michel Gabriel Cazenave1, Katia Mahiou1, Leslie Elahi1
1Surgical Oncology Department, Institut Curie, Site Saint Cloud, Saint-Cloud, France; Institut Curie, Institut des Cancers des Femmes (ANR-23-IAHU-0006), Paris, France.
Background:
Sentinel lymph node biopsy (SLNB) omission is increasingly considered in carefully selected postmenopausal patients with low-risk, early-stage breast cancer. However, the prevalence of occult nodal disease and wether nodal information alters adjuvant management remain key concerns in real-world implementation.
Methods:
We conducted a retrospective, two-center observational study using an institutional REDCap database. Consecutive patients treated surgically between 2023 and 2024 were screened and a strict proxy of ASCO eligibility criteria for SLNB omission was applied (postmenopausal; HR-positive/HER2-negative; invasive ductal carcinoma; T0 to T1; grade 1 to 2; no neoadjuvant therapy). The primary outcome was the prevalence of pN1 disease within the ASCO-eligible cohort. Secondary outcomes included adjuvant chemotherapy use, whole-breast radiotherapy (WBRT), and availability of genomic testing.
Results:
Among 662 screened patients, 211 met all ASCO proxy eligibility criteria. Occult nodal involvement was observed in 20/211 patients (9.5%, pN1). Adjuvant chemotherapy was administered in 10/211 patients (4.7%), while WBRT was delivered in 203/211 (95.7%). Genomic testing was available in 17/211 patients (8.1%) and was predominantly low-risk among those tested (13/17, 76%). Within the pN1 subgroup (n = 20), chemotherapy was administered in 4/20 patients (20%), and genomic testing was available in 8/20 (40%).
Conclusion:
In a real-world cohort meeting strict ASCO proxy criteria, approximately 1 in ten patients had occult pN1 disease, yet chemotherapy use remained uncommon and WBRT was near-universal. These findings suggest nodal status may have limited impact on downstream adjuvant treatment escalation in highly selected low-risk luminal breast cancers.
Related Concept Videos
01:28Menopause
01:21Cancer Survival Analysis
01:12Relative Risk
01:14Assessing Body Temperature - Axilla
Step 1: Perform hand hygiene and put on clean gloves to maintain infection control and prevent cross-contamination.
Step 2: Prepare the patient by explaining the procedure to ensure understanding and cooperation. Ensure privacy, expose the axilla, and inform the patient that minimal movement is crucial for an accurate reading.
Step 3: Adjust the patient’s clothing to expose only the axilla. It minimizes...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...